Agenus on a roll in 2015
Agenus Inc., an immunology company developing novel checkpoint modulators, vaccines and adjuvants to treat cancer, acquired Phoslmmune Inc. last week. Phoslmmune is an immunotherapy company that has discovered a new portfolio of cancer neoantigens. Its equity holders will receive an upfront payment of $2.5 million in cash and $7.4 million in shares of Agenus common stock at closing, plus milestone payments of up to $35 million in cash and/or stock. This acquisition gives Agenus the capacity to expediate the development of new cancer vaccines and other single-agent immuno-oncology approaches, as well as combination therapies. And the deal most likely caps a healthy year for Agenus, which... Read More »Martin Shkreli, We Hardly Knew Ye
Actually, we know Martin Shkreli, CEO of KaloBios Pharmaceuticals (NASDAQ: KBIO), all too well. The brash young man was arrested by the Federal Bureau of Investigations yesterday in Manhattan, on charges of fraud relating to his days at a hedge. Just weeks before, as then-CEO of privately held Turing Pharmaceuticals, he became the poster child of drug price gougers, having boosted the price of a long-marketed generic drug by 5000%, from $13.50 per pill to $750. The revelations in a New York Times story brought swift recriminations from all sides, including presidential candidates. The most striking note for us, as health care database wonks, is that Shkreli launched his first biotech... Read More »Big Deal of the Day: Shire Buys Dyax
Shire plc (NASDAQ: SHPG) is on a buying binge in 2015. After agreeing to be acquired by AbbVie (NYSE: ABBV) for $54.7 billion in July 2014, the deal fell apart in October following the Treasury Department’s revised ruling on foreign domiciles. Shire management turned around and acquired rare disease drug maker NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) in January for $5.2 billion, then added prescription drug maker Meritage Pharma, Inc. in February for $70 million. After a few months digesting those deals, Shire was back on the acquisition trail in August, paying $300 million for Foresight Biotherapeutics Inc., a clincal stage drug development company. Now it’s agreed to pay... Read More »Q3:15 Health Care Dollars, vs. Q2:15
Last week we gave you the breakdown on how the third quarter of 2015 compared with the second quarter and the same quarter a year ago. Here’s how the dollars broke out, versus those quarters. SectorQ3:15Q2:15ChangeQ3:14Change Services Behavioral Health Care$550,000$190,700188%$335,00064% Home Health & Hospice$241,854$0n/a$410,000-41% Hospitals$2,069,865 $2,059,9000.5%$969,800113% Labs, MRI & Dialysis$826,600$1,507,650-45%$324,000155% Long-Term Care$4,175,656$4,141,9300.8%$9,686,200-57% Managed Care$98,000,000$147,00066566%$0n/a Physician Medical Groups$1,600,000$500,000220%$0n/a Rehabilitation $4,300$734,800-99%$163,450-97% Other Services$1,396,474$16,211,644-91%$1,026,40036%... Read More »Q3:15 Health Care Deal Volume
We’re just about to publish our third quarter results this week, but wanted to give you a sneak preview of how the third quarter stacks up against Q2:15 and the same quarter a year ago. Here’s the chart. SectorQ3:15 DealsQ2:15 DealsChangeQ3:14 DealsChange Services Behavioral Health Care10667%4150% Home Health & Hospice9650%15-40% Hospitals332438%1974% Labs, MRI & Dialysis16157%8100% Long-Term Care906538%856% Managed Care12850%5140% Physician Medical Groups1522-32%147% Rehabilitation7617%540% Other Services464015%3628% Services subtotal23819224%19125% Technology Biotechnology413421%27%52% eHealth3334-3%34-3% Medical Devices31297%2619% Pharmaceuticals423811%67-37%... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
